search
Back to results

Weight Regain Treatment Post-Bariatric Surgery

Primary Purpose

Obesity, Overweight

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Behavioral Weight Loss (BWL)
Early Responder: BWL continued
Early Non-responder: BWL continued with medication added
Sponsored by
Yale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity, Overweight

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Be in the age range ≥18 years of age and ≤70 years of age
  • Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and ≤50 kg/m2
  • Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy
  • Experiencing weight regain after bariatric surgery
  • Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators (physical examination, laboratory studies).
  • Read, comprehend, and write English at a sufficient level to complete study-related materials.
  • Provide a signed and dated written informed consent prior to study participation.
  • Be available for participation in the study for up to 3 months.

Exclusion Criteria:

  • Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold).
  • Has a history of anorexia nervosa or history of bulimia nervosa.
  • Is currently taking a medication that is a contraindication to NB medication (e.g., MAOI, opiates).
  • Is currently using other medications for weight loss.
  • Has a history of allergy or sensitivity to bupropion or naltrexone.
  • Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)
  • Has untreated hypertension with a seated systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg, or heart rate > 100 beats/minute.
  • Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke.
  • Has current uncontrolled hypertension.
  • Has current uncontrolled Type I or Type II diabetes mellitus.
  • Has untreated hypothyroidism with a TSH > 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit.
  • Has gallbladder disease.
  • Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder.
  • Has a recent history of drug or alcohol dependence (since having bariatric surgery).
  • Is currently in active treatment for eating or weight loss.
  • Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.
  • Is breast-feeding or is pregnant or is not using a reliable form of birth control.
  • Reports active suicidal or homicidal ideation.

Sites / Locations

  • Yale University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Behavioral Weight Loss

Behavioral Weight Loss + Medication

Arm Description

Outcomes

Primary Outcome Measures

Body Mass Index
BMI is calculated using measured height and weight

Secondary Outcome Measures

Eating Disorder Psychopathology
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
Food Craving
Food craving will be assessed by the Food Craving Inventory
Depressive Symptoms
Depressive symptoms will be assessed by the Patient Health Questionnaire-9. The range is 0-27, which higher scores indicative of greater depressive symptomatology

Full Information

First Posted
December 9, 2020
Last Updated
September 26, 2023
Sponsor
Yale University
Collaborators
American Psychological Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT04662801
Brief Title
Weight Regain Treatment Post-Bariatric Surgery
Official Title
A Behavioral Treatment With Sequenced Adjunctive Pharmacotherapy for Weight Regain After Bariatric Surgery: A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
August 5, 2021 (Actual)
Primary Completion Date
September 13, 2022 (Actual)
Study Completion Date
September 13, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
American Psychological Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will examine behavioral and pharmacologic (Naltrexone+Bupropion) treatments for weight regain after bariatric surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Overweight

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Sequential Assignment
Masking
Outcomes Assessor
Allocation
Non-Randomized
Enrollment
26 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Behavioral Weight Loss
Arm Type
Experimental
Arm Title
Behavioral Weight Loss + Medication
Arm Type
Experimental
Intervention Type
Behavioral
Intervention Name(s)
Behavioral Weight Loss (BWL)
Intervention Description
All participants will receive twelve weeks of BWL treatment.
Intervention Type
Behavioral
Intervention Name(s)
Early Responder: BWL continued
Intervention Description
Participants categorized as experiencing early weight loss at the end of the first month of treatment will continue with BWL for the remainder of treatment.
Intervention Type
Combination Product
Intervention Name(s)
Early Non-responder: BWL continued with medication added
Intervention Description
Participants categorized as not experiencing early weight loss at the end of the first month of treatment will continue BWL plus a weight loss medication (Naltrexone Bupropion) for the remainder of treatment.
Primary Outcome Measure Information:
Title
Body Mass Index
Description
BMI is calculated using measured height and weight
Time Frame
Post-treatment (3 months)
Secondary Outcome Measure Information:
Title
Eating Disorder Psychopathology
Description
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
Time Frame
Post-treatment (3 months)
Title
Food Craving
Description
Food craving will be assessed by the Food Craving Inventory
Time Frame
Post-treatment (3 months)
Title
Depressive Symptoms
Description
Depressive symptoms will be assessed by the Patient Health Questionnaire-9. The range is 0-27, which higher scores indicative of greater depressive symptomatology
Time Frame
Post-treatment (3 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be in the age range ≥18 years of age and ≤70 years of age Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and ≤50 kg/m2 Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy Experiencing weight regain after bariatric surgery Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators (physical examination, laboratory studies). Read, comprehend, and write English at a sufficient level to complete study-related materials. Provide a signed and dated written informed consent prior to study participation. Be available for participation in the study for up to 3 months. Exclusion Criteria: Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold). Has a history of anorexia nervosa or history of bulimia nervosa. Is currently taking a medication that is a contraindication to NB medication (e.g., MAOI, opiates). Is currently using other medications for weight loss. Has a history of allergy or sensitivity to bupropion or naltrexone. Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression) Has untreated hypertension with a seated systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg, or heart rate > 100 beats/minute. Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke. Has current uncontrolled hypertension. Has current uncontrolled Type I or Type II diabetes mellitus. Has untreated hypothyroidism with a TSH > 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit. Has gallbladder disease. Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder. Has a recent history of drug or alcohol dependence (since having bariatric surgery). Is currently in active treatment for eating or weight loss. Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device. Is breast-feeding or is pregnant or is not using a reliable form of birth control. Reports active suicidal or homicidal ideation.
Facility Information:
Facility Name
Yale University
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06511
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Weight Regain Treatment Post-Bariatric Surgery

We'll reach out to this number within 24 hrs